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Background/aim: The primary purpose of this study is to report the experience on the extracorporeal membrane oxygenation (ECMO)
process for patients in the critical care unit (CCU) of an emergency department of a tertiary hospital in Turkey, from cannulation to
decannulation, including follow-up procedures.
Materials and methods: This retrospective and observational study included eight patients who received ECMO from January 2018
to January 2020. We evaluated the demographics, indications for ECMO, laboratory values, Respiratory ECMO Survival Prediction,
Survival After Veno-Arterial ECMO and ECMO net scores, the management process, and patient outcomes. Blood gas analyses done
after the first hour of ECMO initiation and the reevaluation of the patients’ Acute Physiology and Chronic Health Evaluation (APACHE)
II and Sequential Organ Failure Assessment (SOFA) scores in the 24th hour of ECMO were recorded.
Results: The mean age was 52.7 ± 14.2 years. The median duration of the ECMO run was 81 (min–max: 4–267) h, and the mean length
of CCU stay was 10.2 ± 6.7 days. Of the 8 patients studied, 5 (62.5%) had veno-arterial and 3 (37.5%) had veno-venous ECMO. Three
patients were successfully weaned (37.5%). The overall survival-to-discharge rate was 25%. Carbon dioxide levels were significantly
decreased 1 h after ECMO initiation (P = 0.038) as well as the need for vasopressors. Lactate levels were lower in decannulated patients.
Changes in the APACHE II score were more consistent with the clinical deterioration in patients than SOFA score changes were.
Conclusions: In the early phase of ECMO, vital signs improve, and the need for vasopressors and carbon dioxide levels decrease.
Thus, CCUs in Emergency Departments with ECMO capabilities could potentially be designed, and emergency department ECMO
algorithms could be tailored for critically ill patients in addition to out-of-hospital cardiac arrest patients.
Key words: Extracorporeal membrane oxygenation, emergency department, cardiac arrest, resuscitation, critical care

1. Introduction
Extracorporeal membrane oxygenation (ECMO) is
a temporary method for restoring blood flow and
extracorporeal gas exchange while the heart and/or the
lungs rest until the decision for definitive treatment is
made [1]. Since Bartlett et al. first used ECMO successfully
in a newborn with respiratory failure in 1975, it has been a
widespread utility in acute cardiac failure and respiratory
failure due to Acute Respiratory Distress Syndrome (ARDS)
[2–4]. Thus, ECMO has become a vital part of the clinical
practices of cardiovascular surgery and anesthesiology.
As per recent cardiopulmonary resuscitation (CPR)
guidelines [5], extracorporeal (E-CPR) may be considered
an alternative to conventional CPR, and extracorporeal
life support has gained a new perspective. Furthermore,
emergency physician-initiated ECMO programs for outof-hospital cardiac arrest (OHCA) patients have been built

in this decade [6]. However, these programs do not include
patients other than OHCA.
Our study aims to investigate whether the spectrum of
these programs should include other critically ill patients
by reporting the experience of using ECMO in our
emergency department (ED).
2. Materials and methods
2.1. Study population
This study retrospectively analyzed eight ECMO cases from
January 2018 to January 2020 to evaluate demographics,
indications for ECMO, the management process, and
the patients’ outcomes. The study was approved by the
Aydın Adnan Menderes University Committee of Ethics
(Approval No. 2019/109). The ED of Adnan Menderes
University Hospital is a tertiary center with annual
admittance of 100,000 patients. Our ED is unique in that it
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has an intensive care unit (ICU) that is run by emergency
physicians and has a six-bed capacity. It has been serving
as a CCU since 2012. Our ED cares for high-risk referrals
from all nearby cities.
2.2. Patient selection
The patients were selected according to the Extracorporeal
Life Support Organization (ELSO) guidelines [7].
Cardiogenic shock caused by myocardial infarction, sepsis,
or intoxication that did not resolve with the conventional
therapies comprised the main indications for venoarterial (VA) ECMO (Table 1). As for selecting patients for
veno-venous (VV) ECMO, patients with severe hypoxic
respiratory failure, refractory to the maximal medical,
and ventilatory support were determined eligible for this
therapy. In both VA and VV ECMO patients, we strongly
considered whether the patient had a potentially reversible
condition.
Patients with severe irreversible organ failures,
incurable end-stage metastatic malignancies or severe
coagulopathy, and patients older than 75 were considered
not suitable candidates for ECMO.
2.3. ECMO procedure and care
All cannulations were performed by emergency physicians,
either with Seldinger’s method under ultrasonographic
guidance or femoral cut-down. VV ECMO cannulations
were made through the right internal jugular vein and
the femoral vein. Cannulations for VA ECMO were
performed through the femoral vein and the common
femoral artery. A 7-Fr sheath as a back-flow cannula was
placed in the superficial femoral artery in all VA ECMO
patients. For the most part, 19–21-Fr cannulas were used
for arterial access, and 21–23-Fr cannulas were used for
venous drainage. Activated clotting time monitoring was
performed hourly until it reached a steady-state and every
6 h after settling. Moreover, hemoglobin, hematocrit,
platelet, and fibrinogen levels were monitored daily.
In all the cases, we used centrifugal pumps (Maquet
Rotaflow, Maquet Cardiopulmonary AG, Hirrlingen,
Germany) with hollow-fiber membrane oxygenators
(Maquet Quadrox-iD, Maquet Cardiopulmonary AG,
Hirrligen, Germany). The initial pump flow rate (FR) was
set to provide approximately two-thirds of the patient’s
native cardiac output (CO) in the VV ECMO, and the
sweep gas rate was set to two times the pump FR. In cases
of VA ECMO, we initially aimed to set a blood FR of 2–3 L/
min to provide partial assistance and 4–6 L/min when there
was no native CO, such as in asystole. CO was measured,
calculated, and recorded daily by echocardiography in all
the patients.
All of the patients enrolled in this study were
mechanically ventilated. Mechanical ventilatory settings
were adjusted according to either the “lung-protective
ventilation” strategy (Vt 4–6 mL/kg, PEEP 8–10 cm H₂O,
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PIP 25–30 cm H₂O, Rate 15–20/min) or airway pressure
release ventilation mode (inspiration time 4.5 s, expiration
time 0.5 s, high pressure up to 30 cm H₂O, low pressure 0
cm H₂O) in patients receiving VV ECMO. Conventional
mechanical ventilatory settings (e.g., pressure SIMV mode
with tidal volume 6–8 mL/kg, PEEP 5–8 cm H₂O, PIP
15–20 cm H₂O, rate 12–14/min) were mostly used in VA
ECMO patients.
2.4. Weaning from ECMO
When weaning VV ECMO patients, we firstly ensured that
lung-protective ventilation was no longer needed. We then
turned off the gas sweep, suspended the oxygen flow into
the oxygenator, and monitored the patient closely to detect
any increase in respiratory effort. After 6 h of stability,
the patient was considered ready for decannulation. The
weaning trial for VA ECMO patients was done under the
guidance of transthoracic echocardiography. The baseline
left ventricle functions were assessed before the weaning
trial, followed by the pump rate being decreased 1 L/
min. Reassessment of the left ventricular functioning was
made, and an improvement in CO was sought. As long as
the left ventricle allowed, and if the CO was satisfactory,
the decrements of 1 L/min continued until an FR of 1.5 L/
min was achieved. The cannulas were locked with heparin
and clamped for 12 h, mostly overnight. Left ventricle
functions were reassessed, and when there were no
impairments and the patient was stabilized, we proceeded
to the decannulation phase.
Venous cannulas were simply withdrawn, and the
pressure was applied to the site for 20 min. However,
surgical methods, such as vascular wall repair and femoral
fascia suture, were used in the removal of the arterial
cannulas. We also used a Proglide vascular closure device
(Abbott Vascular, Redwood City, CA, USA) in one of our
VA ECMO cases. Postdecannulation venous and arterial
Doppler studies were performed daily at the bedside.
2.5. Data collection
After the decision for the initiation of ECMO was made,
Respiratory ECMO Survival Prediction (RESP) and
ECMO net scores were calculated in the patients who
had VV ECMO; and Survival After Veno-Arterial ECMO
(SAVE) scores were calculated in patients who had VA
ECMO to predict the rate of in-hospital survival. Blood
gas analyses including lactate levels from before and after
the first hour of ECMO initiation, and the reevaluation of
the patients’ APACHE II and SOFA scores at the 24th hour
of ECMO were recorded.
2.6. Data analysis
Statistical analysis was performed using SPSS 20 for
Windows (SPSS Inc., Chicago, IL, USA). The demographic
and clinical data, such as laboratory values, vasoactive
drug infusion rates, and clinical scoring systems, were
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Table 1. The demographic and clinical data of the patients.
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described with mean ± SD and percentages, and ECMO
run duration was described with median (min–max). The
Wilcoxon signed-rank and paired samples t-test were used
to describe the effect of ECMO on laboratory values and
clinical scorings.
3. Results
In our study, a total of 8 patients, 7 males and 1 female,
were included. The mean age was 52.7 ± 14.2 years. The
median duration of the ECMO run was 81 (min–max:
4–267) h, and the mean length of stay in the CCU was 10.2
± 6.7 days. The demographic and detailed clinical data are
presented in Table 1.
VA ECMO was performed in 5 cases (62.5%), and 3
patients were supported with VV ECMO (37.5%). In
addition, a switch to veno-arterio-venous (VAV) ECMO
from VV ECMO was performed in one patient who
developed cardiogenic shock while suffering from ARDS;
and one patient was changed from VA ECMO to VV ECMO
due to the resolution of cardiogenic shock associated with
ARDS (Table 1). These patients’ ECMO type groups were
specified according to the type applied first.
The primary indication for ECMO was ARDS in 4
(50%) patients, intoxication in 2 (25%) patients, sepsis in
1 (12.5%) patient, and ST-Elevation myocardial infarction
(STEMI) in 1 (12.5%) patient (Table 1). Among patients
with ARDS, one patient had fat overload syndrome as
a complication of intravenous lipid emulsion therapy
for suicidal benzodiazepine ingestion; one patient had
H1N1 pneumonia; one patient had invasive pulmonary
aspergillosis, and one patient had bacterial pneumonia
caused by P. aeruginosa. Among the intoxicated patients,
one patient’s intoxication was caused by methanol abuse,
and the other had a digoxin overdose.
The SAVE scores of the VA ECMO and the RESP
and ECMO net scores of the VV ECMO patients are also
presented in Table 1. Three patients (37.5%) were weaned
from ECMO. One of the weaned patients developed
heparin-induced thrombocytopenia after decannulation
and subsequently died. The remaining 2 patients were
discharged (25%) neurologically intact. The overall
survival to the decannulation rate was 37.5%, and the
survival-to-discharge rate was 25%.
Mean pH increased from 7.20 ± 0.17 to 7.30 ± 0.15,
mean pO2 levels increased from 90.4 ± 40.6 mmHg to
127.8 ± 34.9 mmHg, and mean pCO2 levels decreased
from 62.1 ± 30.2 mmHg to 39.1 ± 12.8 mmHg within
the first hour in ECMO support. This decrease in pCO2
levels was statistically significant (P = 0.038). Lactate levels
after the first hour of ECMO increased in four of eight
patients. A decrease in lactate levels after the first hour of
ECMO was recorded in three patients who were able to be
decannulated (Table 2).
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Seven patients needed vasopressor/positive inotropic
agent support. Mean noradrenaline infusion rates were
36.76 ± 30.23 and 34.55 ± 27.12 µg/min, mean adrenaline
infusion rates were 0.10±0.10 and 0.97±0.76 µg/kg/min,
and mean dopamine infusion rates were 27.60 ± 33.48
and 5.12 ± 7.24 µg/kg/min before and after 1 h of ECMO
initiation, respectively (Table 3).
The APACHE II and the SOFA scores prior to ECMO
initiation were 21 ± 2.64 and 11.33 ± 2.88, respectively, in
decannulated patients. The same scores were 24.6 ± 4.98,
and 8.20 ± 3.7, respectively, in nondecannulated patients.
In the 24th hour of ECMO, the APACHE II and SOFA
scores were 19.67 ± 4.5 and 13 ± 4.35, respectively, in
decannulated patients, and 31.2 ± 10.33 and 11.6 ± 2.60, in
nondecannulated patients.
4. Discussion
To our knowledge, our center is the first and only
Emergency Department (ED) to perform ECMO in
Turkey, including all stages of ECMO: patient selection,
cannulation, running, weaning, and discharge. This paper
reports our experience with ECMO in the CCU of our ED.
As a reflection of the variety of patients who are admitted
to our ED, our study population consists of patients with
various presentations and etiologies, such as intoxications
(Table 1).
In a study of intoxicated patients [8], the authors found
that the outcome of the survival rate was significantly
worse in patients with persistent acidosis (in the 24thhour blood gas analysis). Because of the relatively small
sample size and the heterogeneity of our study population,
evaluating whether these parameters are associated with
poor prognosis or not might be misleading. However, we
observed an increase in the lactate levels after the first
hour in deceased patients in our study (Table 2). The
pathophysiology of lactate is much debated, although it is
currently acknowledged that lactate represents more than
merely the anaerobic processes [9]. The only exception to
the increase of the lactate level after the first hour was seen
in Case 8 of our study. However, the lactate began to rise
on the 7th day, and the patient swiftly deteriorated and
died within the following day. Overall, our observation
of the increase in lactate was consistent with the general
medical knowledge and may be valuable for the prognosis
of ECMO patients.
We observed a decrease in inotropic and vasopressor
drug infusion demand after the ECMO initiation (Table
3). In addition to the low demand of vasopressors in Case
4 compared to other patients, this decrease was significant
especially in the patients who survived decannulation
(Cases 5, 6, and 7). However, complications had a major
influence on mortality among these patients. Case 4
developed severe fungemia, and Case 7 developed HIT
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Table 2. Initial and 1 h after the ECMO initiation blood gas analyses of the patients.
Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

Case 7

Case 8

Mean ± SD

Median

Pre-pH

6.93

6.96

7.25

7.13

7.37

7.34

7.31

7.34

7.20 ± 0.17

7.28

Post-pH

7.09

7.26

7.17

7.22

7.38

7.55

7.29

7.49

7.30 ± 0.15

7.27

Pre-O₂ (mmHg)

47.3

69.6

70.0

180.0

99.0

68.9

83.3

105.0

90.4 ± 40.6

76.7

Post-O₂ (mmHg)

57.0

82.7

364.0

133.0

84.9

97.8

93.1

110.0

127.8 ± 97.9

95.4

Pre-CO₂ (mmHg)

108.1

101.0

49.1

75.0

30.7

48.7

26.5

57.8

62.1 ± 30.2

53.4

Post-CO₂ (mmHg)

62.0

31.2

50.9

46.0

25.0

27.9

32.5

37.4

39.1 ± 12.8

34.9

Prelac (mmol/L)

12.8

4.3

1.7

1.0

1.6

1.8

4.9

3,0

3.9 ± 3.8

2.4

Postlac (mmol/L)

17.0

19

10.7

2.7

1.4

1.6

4.7

2.1

7.4 ± 7.2

3.7

Table 3. Doses of vasotropic agents and mean main arterial pressure of the patients before and 1 h after ECMO.

Pre-MAP (mmHg)

Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

Case 7

Case 8

50

66.7

74

76.7

53.3

103.3

100

90

Post-MAP (mmHg)

76.7

86.7

66

68.3

70

90

90

93.3

Prenoradrenaline

63.9

53.2

0

6.6

66.6

-

66.6

37.2

Postnoradrenaline

63.9

53.2

36.9

13.2

66.6

-

42.6

0

Preadrenaline

0.25

0.10

-

-

0.07

-

0.01

-

Postadrenaline

0.20

0.11

0.05

-

0.03

-

-

-

Predopamine

51.3

-

-

-

-

-

-

3.9

Postdopamine

10.2

-

-

-

-

-

-

0

Noradrenaline: µg/min, adrenaline: µg/kg/min, dopamine: µg/kg/min.

after the decannulation, leading both patients to death.
Case 5 had in-hospital cardiac arrest without a history
of comorbidities, and Case 6 did not have any cardiac
compromise that leads to a need for vasopressors.
The APACHE II scores in patients who survived
decannulation prior to ECMO were relatively low
compared to the patients who could not be decannulated.
Furthermore, the APACHE II scores in the 24th hour of
ECMO decreased in this group. By contrast, the SOFA
scores were on the rise during this period. Various scoring
systems have been investigated in critically ill patients. In a
Chinese single-center study [10], the APACHE II score was
found to have a broader application than the SOFA score
did when selecting ARDS patients who may benefit from
VV ECMO. In a study [11] that compared the prognostic
markers in a medical ICU, the APACHE II scoring system
yielded better discrimination power than the SOFA system
did. In light of these data, we suggest that the APACHE
II score may be used to predict the probability of survival

after decannulation in patients who are receiving ECMO
therapy.
Recent reports1 have shown that the survival to
discharge or transfer rate was 29% in E-CPR, 59% in
patients who received pulmonary support, and 43% in
patients who received cardiac support. In our study, Cases
5, 6, and 7 survived decannulation, and Cases 5 and 6
were discharged. We think that several factors may have
contributed to the low survival rate of 25%. One factor
is that the ECMO device was not readily available at our
institution, and when a patient was considered a candidate
for extracorporeal support, the delay that was required to
obtain the device was inevitable. This setback particularly
had a role in Case 3, a patient who received E-CPR. A
recently published metaanalysis [12] suggested that,
compared to conventional CPR, E-CPR showed better
results in survival and neurological outcomes, especially 3
to 6 months after the arrest. However, we believe that the
lack of availability of the ECMO device running on stand-

1
Extracorporeal Life Support Organization (2019). International Summary [online]. Website https://www.elso.org/Registry/Statistics/
InternationalSummary.aspx [accessed 7 October 2019].
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by in the resuscitation bay, especially in Turkey, is a major
obstacle to accomplishing such results. In a study [13], it
was reported that the duration of the mean low-flow state,
particularly over 50 min, is an independent predictor
of mortality. In Case 3, which was our first and the only
E-CPR case, the duration of the low-flow state was around
90 min.
ECMO provides time for the treatment of underlying
reversible causes and thus acts as a bridge to therapy.
However, survival depends on the timing of the reversal of
these causes as well as the timing of the initiation of ECMO
[14,15]. Therefore, survival will be better in cases in which
underlying causes are quickly determined and treated. In
our study, Cases 4 and 8 (aged 30 and 42, respectively)
were initially diagnosed with ARDS due to potential
H1N1 infection. Nevertheless, empirical antibiotics were
promptly initiated because a nosocomial infection could
not be excluded. The initial blood and sputum cultures and
screening for viral pathogens were all negative. However,
the pathogen could only be detected on the 5th to 6th
days of their CCU stays (Aspergillus fumigatus in Case 4
and a resistant strain of Pseudomonas in Case 8). Thus,
a pathogen-specific drug administration was delayed
unintentionally, which might have significantly impacted
their survival. The patients were not able to survive because
they lacked adequate and timely treatment.
In a case series [16] of eight E-CPR patients, where
ECMO was initiated in the ED according to an algorithm,
a survival rate of 27% was reported. Considering that
emergency physicians provide the first medical contact
in all critical patients, including those with cardiac
arrest, prompt patient selection and ECMO initiation by
emergency physicians might improve survival rates. This
suggestion complies with a recently published review
[17] where the authors stated that ECMO may be a
useful tool in the hands of emergency physicians when
a life-threatening situation is present. Furthermore, wellestablished ED ECMO programs for OHCA patients exist
in the literature [18]. In this context, ECMO is gradually
becoming an integral part of the ED, and we suggest that
CCUs be positioned in EDs with ECMO capabilities and
train staff, the combination of which will contribute to
the survival of critically ill patients who need ECMO.

Such a unit could also decrease the risks associated with
transport to the ICU or another hospital with an available
ICU bed. Moreover, by having these CCUs functioning,
ED ECMO algorithms may be evaluated and tailored not
only for OHCA patients, but also for all patients who may
be potential ECMO candidates because of the possibility
of more prompt patient selection.
The major limitation of this study is the small sample
size, making the implications of this study based on mostly
observational data. Only partial statistics could be done,
and the only statistically significant effect of ECMO in
the early phase was the decrease in carbon dioxide levels
though this decrease was foreseeable due to the general
physiology of the ECMO. We may assume that a larger
sample size would better verify or refute our findings
statistically.
5. Conclusions
An improvement in vital signs, laboratory markers, and
a decrease in vasopressor drug demand can be achieved
in the early phase of ECMO. Emergency physicians who
make the first contact with critical patients should be more
familiar with ECMO as resuscitation tends to be more
‘extracorporeal’ in the future. The concept of ED ECMO
may be extended for selected patients who also need
resuscitation with an indication other than a cardiac arrest
as the early initiation of ECMO is associated with better
survival rates.
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